204 related articles for article (PubMed ID: 26854204)
1. Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
Hashimoto S; Mikami S; Sugino H; Yoshikawa A; Hashimoto A; Onodera Y; Furukawa S; Handa H; Oikawa T; Okada Y; Oya M; Sabe H
Nat Commun; 2016 Feb; 7():10656. PubMed ID: 26854204
[TBL] [Abstract][Full Text] [Related]
2. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
[TBL] [Abstract][Full Text] [Related]
3. P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance.
Hashimoto A; Oikawa T; Hashimoto S; Sugino H; Yoshikawa A; Otsuka Y; Handa H; Onodera Y; Nam JM; Oneyama C; Okada M; Fukuda M; Sabe H
J Cell Biol; 2016 Apr; 213(1):81-95. PubMed ID: 27044891
[TBL] [Abstract][Full Text] [Related]
4. High expression of EPB41L5, an integral component of the Arf6-driven mesenchymal program, correlates with poor prognosis of squamous cell carcinoma of the tongue.
Otsuka Y; Sato H; Oikawa T; Onodera Y; Nam JM; Hashimoto A; Fukunaga K; Hatanaka KC; Hatanaka Y; Matsuno Y; Fukuda S; Sabe H
Cell Commun Signal; 2016 Nov; 14(1):28. PubMed ID: 27871329
[TBL] [Abstract][Full Text] [Related]
5. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis.
Hashimoto A; Hashimoto S; Ando R; Noda K; Ogawa E; Kotani H; Hirose M; Menju T; Morishige M; Manabe T; Toda Y; Ishida S; Sabe H
PLoS One; 2011; 6(8):e23359. PubMed ID: 21858086
[TBL] [Abstract][Full Text] [Related]
6. Arf6 and its ZEB1-EPB41L5 mesenchymal axis are required for both mesenchymal- and amoeboid-type invasion of cancer cells.
Handa H; Hashimoto A; Hashimoto S; Sabe H
Small GTPases; 2018 Sep; 9(5):420-426. PubMed ID: 27754741
[TBL] [Abstract][Full Text] [Related]
7. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.
Morishige M; Hashimoto S; Ogawa E; Toda Y; Kotani H; Hirose M; Wei S; Hashimoto A; Yamada A; Yano H; Mazaki Y; Kodama H; Nio Y; Manabe T; Wada H; Kobayashi H; Sabe H
Nat Cell Biol; 2008 Jan; 10(1):85-92. PubMed ID: 18084281
[TBL] [Abstract][Full Text] [Related]
8. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
9. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.
Sabe H; Hashimoto S; Morishige M; Ogawa E; Hashimoto A; Nam JM; Miura K; Yano H; Onodera Y
Traffic; 2009 Aug; 10(8):982-93. PubMed ID: 19416474
[TBL] [Abstract][Full Text] [Related]
10. Mitogenic signaling by lysophosphatidic acid (LPA) involves Galpha12.
Radhika V; Hee Ha J; Jayaraman M; Tsim ST; Dhanasekaran N
Oncogene; 2005 Jun; 24(28):4597-603. PubMed ID: 15856019
[TBL] [Abstract][Full Text] [Related]
11. The EGFR-GEP100-Arf6 pathway in breast cancer: Full invasiveness is not from the inside.
Sabe H; Hashimoto S; Morishige M; Hashimoto A; Ogawa E
Cell Adh Migr; 2008; 2(2):71-3. PubMed ID: 19262097
[TBL] [Abstract][Full Text] [Related]
12. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.
Mikami S; Mizuno R; Kosaka T; Saya H; Oya M; Okada Y
Int J Cancer; 2015 Apr; 136(7):1504-14. PubMed ID: 25123505
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic acid reverses Temsirolimus-induced changes in lipid droplets and mitochondrial networks in renal cancer cells.
Chhabra R; Nanjundan M
PLoS One; 2020; 15(6):e0233887. PubMed ID: 32492043
[TBL] [Abstract][Full Text] [Related]
14. ARF6 and AMAP1 are major targets of
Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
[TBL] [Abstract][Full Text] [Related]
15. GEP100/ARF6 regulates VEGFR2 signaling to facilitate high-glucose-induced epithelial-mesenchymal transition and cell permeability in retinal pigment epithelial cells.
You ZP; Chen SS; Yang ZY; Li SR; Xiong F; Liu T; Fu SH
Am J Physiol Cell Physiol; 2019 Jun; 316(6):C782-C791. PubMed ID: 30540496
[TBL] [Abstract][Full Text] [Related]
16. Machineries regulating the activity of the small GTPase Arf6 in cancer cells are potential targets for developing innovative anti-cancer drugs.
Yamauchi Y; Miura Y; Kanaho Y
Adv Biol Regul; 2017 Jan; 63():115-121. PubMed ID: 27776975
[TBL] [Abstract][Full Text] [Related]
17. ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance.
Hashimoto A; Hashimoto S; Sugino H; Yoshikawa A; Onodera Y; Handa H; Oikawa T; Sabe H
Oncogenesis; 2016 Sep; 5(9):e259. PubMed ID: 27617643
[TBL] [Abstract][Full Text] [Related]
18. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Tsutaho A; Hashimoto A; Hashimoto S; Hata S; Kachi S; Hirano S; Sabe H
Cell Commun Signal; 2020 Jun; 18(1):101. PubMed ID: 32580737
[TBL] [Abstract][Full Text] [Related]
19. The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas.
Komohara Y; Morita T; Annan DA; Horlad H; Ohnishi K; Yamada S; Nakayama T; Kitada S; Suzu S; Kinoshita I; Dosaka-Akita H; Akashi K; Takeya M; Jinushi M
Cancer Immunol Res; 2015 Sep; 3(9):999-1007. PubMed ID: 25783986
[TBL] [Abstract][Full Text] [Related]
20. LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells.
Ward Y; Lake R; Yin JJ; Heger CD; Raffeld M; Goldsmith PK; Merino M; Kelly K
Cancer Res; 2011 Dec; 71(23):7301-11. PubMed ID: 21978933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
